This is the first part of our interview with the esteemed Professor Thomas Borody.

Professor Thomas Borody is a world renowned medical doctor from Australia with over 40 years experience in clinical research and practice, including at the St Vincent Hospital in Sydney and at the Mayo clinic in the US.

Some of his most ground breaking contributions in medical science include the development of a tritherapy for peptic ulcers, the development of faecal microbiota transplants for colitis and other diseases, and recently, a therapy for Crohn disease.
In 1984 he established the Centre for Digestive Diseases in Sydney. He oversaw its growth into an active clinical research institute with 65 employees.
Professor Borody has published numerous articles and is a reviewer for leading international medical journals.
With the pandemic, Professor Borody took a particular interest in researching a therapy for COVID-19, and this is what this interview is all about.

1 month, 2 weeks ago


1 month, 3 weeks ago

TrialSite News productions introduces a new documentary special about Peru, #COVID19 and the acceptance of #Ivermectin as a formally approved treatment for the novel coronavirus. Filmed right in Peru by a Peruvian TrialSite contracted Peruvian film crew, the documentary was commissioned to help other parts of the world better understand why #Peru and the surrounding region have become an epicenter for a community physician movement that advocated for the off-label use of Ivermectin to treat COVID-19 patients. Many doctors there in the South American nation swear by it. In fact, some of them cursed the government for not embracing sooner while other doctors are vehemently opposed to use of the anti-parasitic drug for COVID-19: at least until there is more actual evidence of its efficacy. Watch this original TrialSite production to learn how in fact did Ivermectin become popular in Peru as an Ivermectin treatment? What is the basis and justification for its use? Have formal clinical trials been undertaken there? Why are many physicians fervently pro while others adamantly opposed? What is going on with self -treatment and why that represents trouble in Peru? What is the path forward for Ivermectin as a COVID-19 treatment in Peru, as this South American country might just portend the future for other low-to-middle-income countries as they seek pragmatic ways to battle the novel coronavirus.

2 months ago

Chaine complète: https://www.bitchute.com/channel/AZQZS1dbd6uF/
La télévision australienne SKY NEWS AUSTRALIA fait mention de cette possibilité de traitement. La vidéo est traduite en français mais ne tient que quelques instants sur youtube avant sa censure et sa suppression.

- Annonce de Jeanne Traduction:

- La sauvegarde qu'elle a faite sur sa chaine LBRY.TV:

- La vidéo source en VO sur la chaine Sky News Australia:

2 months ago

Australian researchers tout new 'wonder drug', Ivermectin, as cure for CORONA virus patients. It is cheap and has been on the market for decades.
The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro and has been successfully used to treat COVID patient with almost 100% success rate. The drug has been available since the 1970ies
• Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
• A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.
• Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
• Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.

You just have to watch who is against this and that will tell you all you need to know about the Plandemic.

Read at Science Direct!!!! 👇👇👇👇

2 months ago

Brief Summary:
COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Bangladesh is also struggling in the case of treatment of this disease. Besides antiviral drugs other existing drugs like Hydroxychloroquine, Chloroquine, and recently Ivermectin has been used for the treatment of mild to moderate cases of COVID19 disease. Till now Hydroxychloroquine has shown a good effect. Recently anti-parasitic drug Ivermectin was found highly effective in an in-vitro study against SARS-CoV-2. This study is aimed to evaluate the efficacy of Ivermectin and Hydroxychloroquine as a combination therapy with antibiotics (Doxycyclin and Azithromycin) and compare the recovery period of these two drugs applied as core monotherapy

Brief Summary:
Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.



Clinical Trials and Research News Weekly Roundup | S2 E27 | Ivermectin VS Hydroxychloroquine



2 months ago

Doctors could soon have a new tool in their arsenal for the fight against the coronavirus.

One America's Pearson Sharp has more on the medicine that researchers in Australia say could cure the virus in just 48-hours.

Mirrored from https://www.youtube.com/watch?v=6xklE0jTgaw | One America News Network

2 months, 1 week ago

Democrats are killing people by not allowing this drug to be prescribed. Peer review scientific studies exists and Australian doctors swear by it.

2 months, 1 week ago

Ivermectin, a very common drug, is effective in sever CV19 cases.

4 months, 1 week ago